You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
SBC: Bolder Biotechnology, Inc. Topic: NIAID
DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health